A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Launched by TARGET PHARMASOLUTIONS, INC. · Sep 4, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The TARGET-DERM study is looking at how well current and future treatments work for people with skin conditions like Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, and Chronic Spontaneous Urticaria. This study will track patients over time as they receive treatment in regular clinical settings, helping researchers gather important information on the safety and effectiveness of these therapies.
Anyone from babies to adults who has been diagnosed with one of these skin conditions and has a treatment plan can participate. To join the study, participants should be able to give consent, either themselves or through a parent if they are a child. They should also be planning to visit the clinic for ongoing care. If you decide to join, you’ll simply continue your usual treatment and attend routine visits, while researchers collect information to help improve care for skin conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
- • 2. Participant has plans for future visits at the site for continued management of IMISC.
- Exclusion Criteria:
- • 1. Inability to provide written informed consent/assent.
- • 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Minneapolis, Minnesota, United States
Bronx, New York, United States
Little Rock, Arkansas, United States
Lebanon, New Hampshire, United States
Winston Salem, North Carolina, United States
Kansas City, Kansas, United States
Portland, Oregon, United States
Milwaukee, Wisconsin, United States
Worcester, Massachusetts, United States
Washington, District Of Columbia, United States
Charleston, South Carolina, United States
Oklahoma City, Oklahoma, United States
Richmond, Virginia, United States
East Windsor, New Jersey, United States
Madrid, , Spain
Murray, Utah, United States
Webster, Texas, United States
Pittsburgh, Pennsylvania, United States
Asheville, North Carolina, United States
Lincoln, Nebraska, United States
Louisville, Kentucky, United States
Irvine, California, United States
Fremont, California, United States
Fort Smith, Arkansas, United States
Barcelona, , Spain
Forest Hills, New York, United States
Aurora, Colorado, United States
New York, New York, United States
Murray, Utah, United States
Richmond Hill, Ontario, Canada
Fountain Valley, California, United States
Columbus, Ohio, United States
Montréal, Quebec, Canada
New York, New York, United States
Scottsdale, Arizona, United States
Little Rock, Arkansas, United States
San Diego, California, United States
Hollywood, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Rockville, Maryland, United States
Quincy, Massachusetts, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Wyckoff, New Jersey, United States
Buffalo, New York, United States
East Syracuse, New York, United States
Rockville Centre, New York, United States
El Paso, Texas, United States
Lewisville, Texas, United States
Spokane, Washington, United States
Morgantown, West Virginia, United States
Peterborough, Ontario, Canada
Mahlow, Bradenburg, Germany
Lübeck, Schleswig Holstein, Germany
Frisco, Texas, United States
Mill Creek, Washington, United States
Chapel Hill, North Carolina, United States
Düren, Nrw, Germany
Little Rock, Arkansas, United States
Saskatoon, Saskatchewan, Canada
Brooklyn, New York, United States
Richmond Hill, Ontario, Canada
Patients applied
Trial Officials
Laura Dalfonso
Study Director
Target RWE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials